TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19086875

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS) at doses ranging from 50 to 400 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS)
Number of subjects: 0
Study: 16360211

Group type: EXPERIMENTAL
Intervention: 0.1% prednisolone drops
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.1% hyaluronic acid drops
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 41
Study: 15325501

Group type: EXPERIMENTAL
Intervention: Infant formula with nucleotides added
Number of subjects: 12

Group type: COMPARATOR
Intervention: Infant formula without nucleotides
Number of subjects: 12
Study: 11102741

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9057957

Group type: EXPERIMENTAL
Intervention: losartan potassium
Number of subjects: 29

Group type: COMPARATOR
Intervention: felodipine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: losartan potassium (diabetic group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: felodipine (diabetic group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: losartan potassium (non-diabetic group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: felodipine (non-diabetic group)
Number of subjects: 29
Study: 8358407

Group type: EXPERIMENTAL
Intervention: Individualized oral hygiene instruction and dental supplies (dental mirror and red disclosing tablets)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No oral hygiene instruction or supplies (Control)
Number of subjects: 20
Study: 2439823

Group type: EXPERIMENTAL
Intervention: 0.5 mg bopindolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 1 mg bopindolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29396603

Group type: EXPERIMENTAL
Intervention: Annular closure device (ACD) implantation
Number of subjects: 493

Group type: COMPARATOR
Intervention: Limited lumbar discectomy alone (Control)
Number of subjects: 493
Study: 26754303

Group type: EXPERIMENTAL
Intervention: 12.5 mg paroxetine controlled-release tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 25 mg paroxetine controlled-release tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 37.5 mg paroxetine controlled-release tablet
Number of subjects: 12
Study: 23953097

Group type: EXPERIMENTAL
Intervention: ReSTOR SN6AD3 (Alcon Laboratories, Inc)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ReSTOR SN6AD1 (Alcon Laboratories, Inc)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: TECNIS ZMA00 (Abbott Medical Optics)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study: 22897903

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program in a rehabilitation centre, applied three times a week for 3 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Flexibility and relaxation program in a rehabilitation centre, applied three times a week for 3 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Daily physical activity program set at home using pedometers
Number of subjects: 150
Study: 20214443

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CTG plus restoration (CTG + R)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CTG
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CAF and CAF + R (overall data)
Number of subjects: 78
Study: 18596310

Group type: COMPARATOR
Intervention: Standard glutamine-free amino acids (STD-PN)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Glutamine dipeptide-supplemented parenteral nutrition (GLN-PN)
Number of subjects: 59

Group type: COMPARATOR
Intervention: STD-PN
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: GLN-PN
Number of subjects: 59
Study: 16018759

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 15
Study: 12091203

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10870905

Group type: EXPERIMENTAL
Intervention: Happy mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sad mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood
Number of subjects: 0
Study: 9096188

Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg every 12 h for three doses then daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Flucloxacillin (1 g every 6 h i.v./p.o.)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Flucloxacillin
Number of subjects: 64
Study: 8212206

Group type: EXPERIMENTAL
Intervention: UW solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: EC solution
Number of subjects: 0
Study: 3090827

Group type: EXPERIMENTAL
Intervention: Splenectomy (in 12 out of 17 patients)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-responsive ITP patients (not treated with splenectomy)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Splenectomy (in patients not cured)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Splenectomy (in 2 patients after relapse)
Number of subjects: 35
Study: 30260145

Group type: EXPERIMENTAL
Intervention: Stem cells therapy in addition to surgical left ventricular restoration (SVR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26584627

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26091669

Group type: EXPERIMENTAL
Intervention: PREDICT intervention (allied dental personnel providing screening and preventive services in community settings with pay-for-performance compensation)
Number of subjects: 82000

Group type: COMPARATOR
Intervention: Control intervention (care delivered in dental offices without performance incentives)
Number of subjects: 82000
Study: 23795877

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 332
Study: 21701685

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise plus protein (EX+PRO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 24
Study: 19653787

Group type: EXPERIMENTAL
Intervention: smoked marijuana with 2.8% THC
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 16722953

Group type: EXPERIMENTAL
Intervention: Standard music (n = 22)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patterning music (n = 18)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 60
Study: 15204043

Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 36
Study: 10742708

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 201
Study: 9041468

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon-beta (IFN-beta) at a dosage of 6 million units three times per week for 6 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon-beta (IFN-beta)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 90
Study: 7701045

Group type: EXPERIMENTAL
Intervention: Ipsapirone 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipsapirone 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3299181

Group type: EXPERIMENTAL
Intervention: Five different techniques of cuff closure during transvaginal hysterectomy
Number of subjects: 112
Study: 29788545

Group type: EXPERIMENTAL
Intervention: Aromatherapy with Rosa damascena at a 4% concentration
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group receiving aromatherapy with 100% sweet almond oil
Number of subjects: 66
Study: 28219804

Group type: EXPERIMENTAL
Intervention: Unilateral posterior‐to‐anterior mobilization (PA) applied to the neck
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (PA-P) applied to the neck (light touch on the right 6th cervical vertebra)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both PA and PA-P
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PA
Number of subjects: 44
Study: 26174461

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily, increased to 100 mg after 1 week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23446104

Group type: EXPERIMENTAL
Intervention: Exercise for 15 weeks
Number of subjects: 48
Study: 21203367

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 59
Study: 18286296

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB), 1.25 mg, 5‐7 days before PPV
Number of subjects: 22

Group type: COMPARATOR
Intervention: Direct PPV (Control group)
Number of subjects: 22
Study: 16448519

Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide 500/2.5 mg tablets (initial daily dose 1000/5 mg)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Metformin 500 mg plus rosiglitazone 4 mg (initial daily dose 1000-2000 mg + 4 mg)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide
Number of subjects: 318

Group type: COMPARATOR
Intervention: Metformin plus rosiglitazone
Number of subjects: 318
Study: 12923399

Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP)
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP)
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP)
Number of subjects: 3007
Study: 10708289

Group type: EXPERIMENTAL
Intervention: RTV/SQV
Number of subjects: 167

Group type: COMPARATOR
Intervention: RTV/SQV/d4T
Number of subjects: 167
Study: 9401428

Group type: EXPERIMENTAL
Intervention: Pleasant odor
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Unpleasant odor
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-odor control
Number of subjects: 80
Study: 8587251

Group type: EXPERIMENTAL
Intervention: ACE DD genotype
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: non-DD genotype
Number of subjects: 180
Study: 2667746

Group type: EXPERIMENTAL
Intervention: Adjuvant progestagen therapy (progesterone)
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Control group (no additional therapy)
Number of subjects: 1148
Study: 1069314

Group type: EXPERIMENTAL
Intervention: 250 mcg/kg N,N-Dimethyltryptamine (DMT) i.m.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31121324

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) until progression, unacceptable toxicity, or consent withdrawal
Number of subjects: 1426
Study: 29028930

Group type: EXPERIMENTAL
Intervention: MAX (smartphone application)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (without MAX)
Number of subjects: 46
Study: 26041274

Group type: EXPERIMENTAL
Intervention: Immediate injection of botulinum toxin type A (group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 1-month delayed injection of botulinum toxin type A (group B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 34
Study: 25099322

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol-remifentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Volatile anesthesia with desflurane-remifentanil
Number of subjects: 30
Study: 22230384

Group type: EXPERIMENTAL
Intervention: Enalapril-FA tablet (10:0.4 mg, low FA group)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Enalapril-FA tablet (10:0.8 mg, high FA group)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Enalapril only (10 mg, control group)
Number of subjects: 480
Study: 18996525

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 17204992

Group type: EXPERIMENTAL
Intervention: Virtual Reality Temporal Bone (VR TB) simulator
Number of subjects: 19
Study: 16192600

Group type: EXPERIMENTAL
Intervention: YES-ASP (20 weekly doses of high-dose L-asparaginase at 25,000 IU/m2)
Number of subjects: 494

Group type: COMPARATOR
Intervention: NO-ASP (no high-dose L-asparaginase)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 494
Study: 12475845

Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 9806581

Group type: EXPERIMENTAL
Intervention: PCR-positive for C. trachomatis DNA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Presence of chlamydial RNA molecules
Number of subjects: 10
Study: 8961906

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) at a dosage of 2,000 mg/day
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 1820496

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7295884

Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide dinitrate (30 mg) in combination with standard-release pindolol (7.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-release isosorbide dinitrate alone (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-release pindolol alone (7.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained-release pindolol (7.5 mg) in combination with isosorbide dinitrate
Number of subjects: 0
Study: 31503365

Group type: EXPERIMENTAL
Intervention: Elective Delivery (ED) at 34 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 21
Study: 31843012

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 28116754

Group type: EXPERIMENTAL
Intervention: Esoxx (hyaluronic acid-chondroitin sulphate based bioadhesive formulation) plus standard dose PPIs
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo plus standard dose PPIs
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Esoxx plus standard dose PPIs
Number of subjects: 154
Study: 25944731

Group type: COMPARATOR
Intervention: Bisphosphonates
Number of subjects: 2464
Study: 23352732

Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillotomy (TT)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Bipolar scissors tonsillectomy (TE)
Number of subjects: 193
Study: 21811062

Group type: EXPERIMENTAL
Intervention: Dried California Mission figs (120 g/day) added to usual diet for 5 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual diet for 5 weeks
Number of subjects: 83
Study: 19455481

Group type: EXPERIMENTAL
Intervention: Recovery beverage (40 g CHO + 20 g PRO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study: 16938699

Group type: EXPERIMENTAL
Intervention: Larger associative fan (more associates paired with event-based cues)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absolute strength of an association
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiarity of background words
Number of subjects: 0
Study: 15549278

Group type: EXPERIMENTAL
Intervention: SSRI treatment (paroxetine or citalopram) for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (non-clinical sample)
Number of subjects: 19
Study: 11104597

Group type: EXPERIMENTAL
Intervention: Fortified menu
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal menu
Number of subjects: 0
Study: 1626500

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 6497566

Group type: EXPERIMENTAL
Intervention: Haloperidol (fixed doses)
Number of subjects: 0
Study: 31403675

Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 8184

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 8184
Study: 29229955

Group type: EXPERIMENTAL
Intervention: Whole milk (3.5% fat)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Skimmed milk (0.1% fat)
Number of subjects: 18
Study: 27072159

Group type: EXPERIMENTAL
Intervention: Left lateral position for 15 minutes followed by right lateral position for another 15 minutes (Group 1)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Right lateral position for 15 minutes followed by left lateral position for another 15 minutes (Group 2)
Number of subjects: 69
Study: 24074763

Group type: EXPERIMENTAL
Intervention: Adjuvant 5-flurouracil, alpha-interferon and interleukin-2
Number of subjects: 309

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 309
Study: 23082382

Group type: EXPERIMENTAL
Intervention: In-office bleaching with 35% hydrogen peroxide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: At-home bleaching with 16% carbamide peroxide
Number of subjects: 60
Study: 20442660

Group type: EXPERIMENTAL
Intervention: Remifentanil 7.8 microg kg(‐1) (IED95)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg kg(‐1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Remifentanil doses (3, 4, 5, or 6 microg kg(‐1))
Number of subjects: 68
Study: 19100036

Group type: EXPERIMENTAL
Intervention: Interventional therapy
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Surgical operations
Number of subjects: 232

Group type: COMPARATOR
Intervention: Congenital Heart Disease (CHD)
Number of subjects: 232
Study: 15472910

Group type: EXPERIMENTAL
Intervention: Oral Etoposide
Number of subjects: 495

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 495

Group type: COMPARATOR
Intervention: 3-drug combination (actinomycin-D, vincristine, bleomycin)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 495
Study: 12583787

Group type: COMPARATOR
Intervention: NEI-VFQ scores for participants with advanced age-related macular degeneration, severe nuclear opacity, reduced visual acuity, or cataract surgery
Number of subjects: 4077

Group type: EXPERIMENTAL
Intervention: NEI-VFQ subscales
Number of subjects: 4077
Study: 10565801

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-150 mg/day)
Number of subjects: 15
Study: 8902369

Group type: EXPERIMENTAL
Intervention: Automated detection method using textural features in scintigraphic images
Number of subjects: 23
Study: 2007841

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg b.i.d. for 2 weeks followed by 10 mg b.i.d. for a further 2 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6442151

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg or 500 mg, 12-hourly for 10 days
Number of subjects: 40
Study: 31656505

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (group A, n=25)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (group B, n=25)
Number of subjects: 40
Study: 29366703

Group type: EXPERIMENTAL
Intervention: Single dose of bivalent HPV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three doses of HPV vaccine
Number of subjects: 0
Study: 26084406

Group type: EXPERIMENTAL
Intervention: Meropenem (1 g/8 hours) plus Daptomycin (6 mg/kg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ceftazidime (2 g/8 hours)
Number of subjects: 32
Study: 24390407

Group type: EXPERIMENTAL
Intervention: untargeted UPLC‐qTOF‐MS metabolomics analysis on urine samples
Number of subjects: 107

Group type: COMPARATOR
Intervention: previous meal study
Number of subjects: 107
Study: 23727737

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2g sodium perborate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (0.04 ml distilled water)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison among carbamide peroxide, sodium perborate, and hydrogen peroxide after two bleaching sessions (day 14)
Number of subjects: 40
Study: 21995695

Group type: EXPERIMENTAL
Intervention: Doxazosin gastrointestinal therapeutic system (GITS) 4 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg
Number of subjects: 207
Study: 18280222

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study: 16153674

Group type: EXPERIMENTAL
Intervention: Training in grating detection in the amblyopic eye near pre‐training cut‐off spatial frequency
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Training regimen of repeated contrast‐sensitivity function measurements in the amblyopic eye
Number of subjects: 23

Group type: COMPARATOR
Intervention: No training (Control Group III)
Number of subjects: 23
Study: 14578408

Group type: EXPERIMENTAL
Intervention: Ibopamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tropicamide
Number of subjects: 24
Study: 10973645

Group type: EXPERIMENTAL
Intervention: Stage-of-change oriented smoking cessation intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 204
Study: 8788832

Group type: EXPERIMENTAL
Intervention: Discarding 1.5 ml of blood from the catheter
Number of subjects: 9
Study: 1740940

Group type: EXPERIMENTAL
Intervention: Glucose (G)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glucose and lipid (GF)
Number of subjects: 18
Study: 6131635

Group type: EXPERIMENTAL
Intervention: Almitrine (0.5 mg/kg/h for 2 h)
Number of subjects: 11
Study: 30278263

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Structured Exercise (SE) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RIC plus SE
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 40
Study: 30146935

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 5022

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5022
Study: 26719915

Group type: EXPERIMENTAL
Intervention: telmisartan/amlodipine
Number of subjects: 75

Group type: COMPARATOR
Intervention: telmisartan/hydrochlorothiazide
Number of subjects: 75